Vandetanib (ZD6474) in the treatment of medullary thyroid cancer

Clinical Medicine Insights: Oncology

Volumn 5, Issue , 2011, Pages 213-221

  Deshpande, Hari ^a,b   Roman, Sanziana ^a   Thumar, Jaykumar ^a,b   Sosa, Julie Ann ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

Medullary thyroid cancer; Vandetanib; Zactima; ZD6474

Indexed keywords

AXITINIB; CABOZANTINIB; CAPECITABINE; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; MOTESANIB; PLACEBO; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN C; XL 184;

ADVANCED CANCER; CYTOPENIA; DIARRHEA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG WITHDRAWAL; FATIGUE; FOOD AND DRUG ADMINISTRATION; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; LIVER FUNCTION TEST; METASTASIS; MOLECULAR INTERACTION; NAUSEA; PROGRESSION FREE SURVIVAL; PROTEINURIA; QT PROLONGATION; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; STOMATITIS; SUDDEN DEATH; THYROID MEDULLARY CARCINOMA; TORSADE DES POINTES;

EID: 84860389208     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S6197     Document Type: Review

References (37)

1. Carling T, Udelsman R. Thyroid tumors, in Cancer: Principles and Practice of Oncology, DeVita VT, Hellman S, Rosenberg SA, editors. 2008, Lippincott Williams & Wilkins: Philadelphia, PA; 1663-82.
2. Hazard JB, Hawk WA, Crile G Jr. Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. J Clin Endocrinol Metab. 1959;19(1):152-61.
3. Friedell GH, Carey RJ, Rosen H. Familial thyroid cancer. Cancer. 1962;15: 241-5.
4. Sipple JH. The association of pheochromocytoma with carcinoma of the thyroid gland. The American Journal of Medicine. 1961;31(1):163-6.
5. Steiner AL, Goodman AD, Powers SR. Study of a kindred with pheochro-mocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cush-ing's disease: multiple endocrine neoplasia, type 2. Medicine (Baltimore). 1968; 47(5):371-409.
6. Sakorafas GH, Friess H, Peros G. The genetic basis of hereditary medullary thyroid cancer: clinical implications for the surgeon, with a particular emphasis on the role of prophylactic thyroidectomy. Endocr Relat Cancer. 2008;15(4):871-84.
7. Brandi ML, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86(12):5658-71.
8. Pacini F, et al. Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol). 2010;22(6):475-85.
9. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107(9):2134-42.
10. Deshpande HA, Gettinger SN, Sosa JA. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope. Curr Opin Oncol. 2008;20(1):19-24.
11. Druker BJ, et al. Activity of a specifc inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344(14): 1038-42.
12. Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol. 1999;17(1):380-93.
13. Eng C, et al. The relationship between specifc RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276(19):1575-9.
14. Messina M, Robinson BG. Technology insight: gene therapy and its potential role in the treatment of medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab. 2007;3(3):290-301.
15. Schimke RN, Hartmann WH. Familial amyloid-producing medullary thyroid carcinoma and pheochromocytoma. A distinct genetic entity. Ann Intern Med. 1965;63(6):1027-39.
16. Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 1985;42(2):581-8.
17. Capp C, et al. Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid. 2010;20(8):863-71.
18. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-76.
19. Wedge SR, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002;62(16):4645-55.
20. Carlomagno F, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, effciently blocks oncogenic RET kinases. Cancer Res. 2002; 62(24):7284-90.
21. Herbst RS, et al. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs. 2007;16(2):239-49.
22. Holden SN, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol. 2005;16(8):1391-7.
23. Tamura T, et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol. 2006;1(9):1002-9.
24. Wells SA Jr, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28(5):767-72.
25. Haddad RI, KA, Vasselli J, et al. A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2008;26(Suppl):322s.
26. SA W. OC-021. in The 14th International Thyroid Congress. 2010. Paris, France.
27. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM235092.pdf.
28. Ahuja S, Ernst H. Chemotherapy of thyroid carcinoma. J Endocrinol Invest. 1987;10(3):303-10.
29. Matuszczyk A, et al. Chemotherapy with paclitaxel and gemcitabine in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res. 2010;42(1):61-4.
30. Gilliam LK, et al. Capecitabine therapy for refractory metastatic thyroid carcinoma: a case series. Thyroid. 2006;16(8):801-10.
31. Kurzrock R, Sherman SI, Pfster RB, et al. Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET. Journal of Clinical Oncology, 2010 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2010; Vol 28 (No 15_suppl (May 20 Supplement)).
32. Kurzrock R, Hong D. A phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies including a subgroup of patients with medullary thyroid cancer (MTC). in 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2008. Geneva, Switzerland.
33. Schlumberger MJ, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009;27(23):3794-801.
34. Deshpande HA, Gettinger S, Sosa JA. Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer. Core Evid. 2010;4:43-8.
35. Cohen EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008; 26(29):4708-13.
36. Lam ET, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010;28(14):2323-30.
37. Carr LL, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010; 16(21):5260-8.